Virpax resolves Nasdaq delisting, appoints new director, extends NIH collaboration, posts positive Probudur results

Virpax Pharmaceuticals, Inc.

On Nov 19, Virpax cured Nasdaq delisting notice by appointing Esha Randhawa as independent director and audit committee member.
CEO Jatinder Dhaliwal entered contractor agreement; annual fee $200k plus milestone incentives tied to IND, trials, FDA approval.
NIH/NCATS extended collaboration for NES100 intranasal enkephalin pain candidate, aiming for IND for acute/chronic non-cancer pain.
Probudur minipig DRF study showed positive tolerance, no adverse effects; supports IND filing for long-acting bupivacaine formulation.

item 3.01 item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Esha Randhawa

Independent Director

Virpax Pharmaceuticals, Inc.

Effective: 2024-11-19
Filed: November 22, 2024, 6:59 PM ET

on November 19, 2024, the Board appointed Ms. Esha Randhawa to serve as an independent director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Esha Randhawa was appointed as Independent Director at Virpax Pharmaceuticals, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

on November 19, 2024, the Board appointed Ms. Esha Randhawa to serve as an independent director of the Company, effective immediately.

View on SEC.gov

Source: SEC EDGAR

accession 0001731122-24-001845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.